Psoriatic arthritis: Treatment strategies using biologic agents

Reumatismo

Volumn 64, Issue 2, 2012, Pages 113-121

  D'Angelo, S ^a   Palazzi, C ^a   Olivieri, I ^a  

^a Madonna Delle Grazie Hospital of Matera   (Italy)

Author keywords

Anti TNF agents; Biologic drugs; Psoriatic arthritis; Psoriatic disease; Therapy

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; PHARMACOLOGICAL BLOCKING; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84862487609     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2012.113     Document Type: Review

References (53)

1. Gladman DD. Psoriatic arthritis. In: Harris ED Jr, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB, editors. Kelley's Textbook of Rheumatology. 7th ed. Philadelphia: Elsevier Saunders. 2005; 1155-1164.
2. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006; 33: 210-212.
3. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003; 42: 778-783.
4. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990; 17:809-812.
5. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
6. Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis. 1999; 58: 226-229.
7. Scarpa R, Cuocolo A, Peluso R, Atteno M, Gisonni P, Iervolino S, et al. Early psoriatic arthritis: the clinical spectrum. J Rheumatol. 2008; 35: 137-141.
8. Lindqvist UR, Alenius GM, Husmark T, The-ander E, Holmström G, Larsson PT. Psoriatic Arthritis Group of the Society for Rheumatology. The Swedish early psoriatic arthritis register- 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008; 35: 668-673.
9. Gladman DD, Farewell VT, Husted J, Wong K. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998; 41: 1103-1110.
10. Gladman DD. Disability and quality of life considerations. Psoriatic arthritis. In Gordon GB, Ruderman E, eds. Psoriatic and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag. 2005; 118-123.
11. Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006; 33: 1417-1421.
12. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264-2272.
13. Kavanaugh A, Antoni CE, Gladman D, Was-senberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radio-graphic analyses after 1 year. Ann Rheum Dis. 2006; 65: 1038-1043.
14. Mease PJ, Gladman DD, Ritchlin CT, Ru-derman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psori-atic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279-3289.
15. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Go-limumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in pso-riatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60: 976-986.
16. Olivieri I, D'Angelo S, Padula A, Palazzi C. The challenge of early diagnosis of psoriatic arthritis. J Rheumatol. 2008; 35: 3-5.
17. Gladman DD. Can we identify psoriatic arthritis early? Curr Rheumatol Rep 2008; 10: 419-21.
18. Olivieri I, D'Angelo S, Palazzi C, Padula A. Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother. 2009; 10: 271-282.
19. Anandarajah AP, Ritchlin CT. The diagnosis of early psoriatic arthritis. Nat Rev Rheuma-tol. 2009; 5: 634-641.
20. Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol. 2011; 30: 1063-1067.
21. Olivieri I, D'Angelo S, Palazzi C, Lubrano E, Leccese P. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2010; 15: 399-414.
22. Veale DJ, Ritchlin C, FitzGerald O. Immu-nopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005; 64 (Suppl. II): ii26-ii29.
23. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials. J Rheumatol. 2008; 35: 883-890.
24. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, Fitzgerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012; 71: 319-326.
25. Saad AA, Hyrich KL, Ashcroft DM. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis. Expert Opin Drug Saf. 2011; 10: 219-226.
26. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008; 67: 364-369.
27. Saad AA, Ashcroft DM, Watson KD, Sym-mons DP, Noyce PR, Hyrich KL; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010; 49: 697-705.
28. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and anky-losing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther. 2011; 13 (Suppl. 1): S4.
29. Lubrano E, Spadaro A, Marchesoni A, Oliv-ieri I, Scarpa R, D'Angelo S, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol. 2011; 29: 80-84.
30. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64: 1150-1157.
31. Antoni CE, Kavanaugh A, Kirkham B, Tu-tuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005; 52: 1227-1236.
32. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Inf-liximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol. 2005; 32: 2183-2185.
33. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007; 66: 1393-1397.
34. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009; 11: R52.
35. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al. Infliximab inhibits progression of radio-graphic damage in patients with active pso-riatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007; 56: 2698-2707.
36. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008; 35: 869-876.
37. Palazzi C, D'Angelo S, Cantini F, Lubrano E, Marchesoni A, Mathieu A, et al. Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol. 2011; 29: 858-864.
38. D'Angelo S, Palazzi C, Cantini F, Lubrano E, Marchesoni A, Mathieu A, et al. Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol. 2011; 29: 865-870.
39. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007; 56: 476-488.
40. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009; 68: 702-709.
41. Kavanaugh A, Mease P, Krueger GG, Glad-man D, Zrubek J, Beutler A, et al. Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2009; 68 (Suppl. 3): 136.
42. ® study. Arthritis Rheum 2012 Feb 29. doi:10.1002/ art.34436. [Epub ahead of print].
43. Davidoff F, Case K, Fried PW. Evidence-Based Medicine: Why all the fuss? Ann Intern Med. 1995; 122: 727.
44. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009; 68: 1387-1394.
45. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psori-atic arthritis with pharmacological therapies. Ann Rheum Dis. 2012; 71: 4-12.
46. Salvarani C, Pipitone N, Marchesoni A, Can-tini F, Cauli A, Lubrano E, et al. Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol. 2011; 29 (3 Suppl. 66): S28-41.
47. Olivieri I, D'Angelo S, Palazzi C, Padula A, Lubrano E, Mantovani LG. Pharmacoeco-nomic issues in psoriatic arthritis. J Rheu-matol 2012, in press.
48. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. The psori-atic arthritis cost evaluation (PACE) study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford). 2008; 47: 1664-1670.
49. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford). 2006; 45: 1029-1038.
50. Bravo Vergel Y, Hawkins NS, Claxton K, As-seburg C, Palmer S, Woolacott N, et al. The cost-effectiveness of etanercept and inflix-imab for the treatment of patients with psori-atic arthritis. Rheumatology (Oxford). 2007; 46: 1729-1735.
51. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Knadjesari Z, Misso K, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2006; 10: 1-239.
52. Cummins E, Assenburg C, Prasad D, Buchanan J, Punekar YS. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2011 Jul 1 [Epub ahead of print].
53. Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, inflix-imab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011; 15: i-xxi, 1-329.